WallStSmart

Cumberland Pharmaceuticals Inc (CPIX)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 33164% more annual revenue ($14.74B vs $44.30M). VTRS leads profitability with a -2.8% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 1.05. VTRS earns a higher WallStSmart Score of 48/100 (D+).

CPIX

Avoid

23

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.28

VTRS

Hold

48

out of 100

Grade: D+

Growth: 2.7Profit: 3.5Value: 4.3Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CPIXUndervalued (+14.2%)

Margin of Safety

+14.2%

Fair Value

$4.51

Current Price

$6.39

$1.88 discount

UndervaluedFair: $4.51Overvalued
VTRSSignificantly Overvalued (-85.0%)

Margin of Safety

-85.0%

Fair Value

$8.72

Current Price

$16.51

$7.79 premium

UndervaluedFair: $8.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CPIX1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

VTRS1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

CPIX4 concerns · Avg: 3.3/10
PEG RatioValuation
1.674/10

Expensive relative to growth rate

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$95.74M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-29.8%2/10

ROE of -29.8% — below average capital efficiency

VTRS4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CPIX

The strongest argument for CPIX centers on Debt/Equity.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : CPIX

The primary concerns for CPIX are PEG Ratio, EPS Growth, Market Cap.

Bear Case : VTRS

The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.

Key Dynamics to Monitor

VTRS carries more volatility with a beta of 0.88 — expect wider price swings.

VTRS is growing revenue faster at 4.9% — sustainability is the question.

VTRS generates stronger free cash flow (329M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (48/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cumberland Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and marketing of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company is headquartered in Nashville, Tennessee.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?